First patient enrolled in pilot cataract trial assessing lanosterol eye drop ZOC2017217

Multicenter pilot informs phase III design

According to a new announcement from Lexitas Pharma Services and Ocusun, the first patient has enrolled in a pilot study of ZOC2017217, an investigational topical eye drop for age-related cataract.¹ Enrollment took place at North Bay Eye Associates in Petaluma, California, under investigator Jason Bacharach, MD.¹ The pilot is designed to inform an upcoming pivotal Phase 3 program.¹

ODs frequently manage patients with early lens changes before surgical referral becomes necessary. A pharmacologic option targeting cataract progression would give optometrists a new tool for monitoring and counseling patients who are not yet surgical candidates. Currently, cataract surgery remains the only established treatment, and no topical agent has demonstrated confirmed efficacy in restoring lens clarity in controlled human trials.²

The multicenter, randomized, double-masked, placebo-controlled pilot study (NCT07395986) is evaluating the efficacy and safety of ZOC2017217 in participants with age-related cataract.¹ The trial began enrollment in February 2026, carries an estimated primary completion date of March 2027, and an estimated study completion date of May 2027.³ ZOC2017217 is derived from lanosterol, a naturally occurring sterol studied for its potential to reduce protein misfolding and aggregation associated with cataract formation.¹

"The enrollment of our first patient marks an important milestone for the ZOC2017217 program, building on encouraging data from our exploratory study in China where 50.0% to 86.4% of participants achieved a visual acuity of 20/40 or better 12 to 24 weeks post-treatment. ZOC2017217 indicates a potential alternative treatment approach that could reshape the landscape of cataract care," said Terrence Li, Chief Medical Officer and Chief Operating Officer of Ocusun, in a news release.¹ "By pioneering this innovative development strategy, our objective is to deliver a new treatment option that addresses the significant unmet need for age-related cataract treatment globally.”¹

Safety data remain limited so far

Detailed secondary endpoint and safety data from the pilot have not yet been reported publicly. In preclinical work, ZOC2017217 improved antioxidant activity and reduced lens opacity by inhibiting protein aggregation associated with cataract formation.¹ Early clinical findings suggest the agent may improve visual function, reduce lens opacity, and enhance vision-related quality of life, though full safety and tolerability data from the pilot have not been released.¹

Independent confirmation of lanosterol-based mechanisms in humans has been mixed. A laboratory study found lanosterol failed to dissolve aggregated proteins or restore clarity in cultured human cataractous lens nuclei, and a separate case report found lanosterol eye drops produced no clinical benefit in a patient with unilateral juvenile nuclear cataract.² ODs should weigh this history of inconsistent human data when discussing ZOC2017217 with patients ahead of confirmatory Phase 3 results.

"Cataracts remain one of the leading causes of vision impairment worldwide, and the development of a potential non-surgical treatment represents an exciting opportunity to advance patient care," said Jeanne Hecht, Chief Executive Officer of Lexitas Pharma Services, in the release. "We are proud to support Ocusun in generating the clinical evidence needed to assess the potential of this innovative therapy and help inform the program's continued development."

ZOC2017217 remains investigational, and optometrists cannot prescribe it outside the clinical trial setting. ODs comanaging patients with early cataract can consider referring eligible candidates to participating sites, since physicians may direct inquiries to Lexitas for eligibility information.¹ Monitoring protocols and patient counseling on cataract progression are unlikely to change until confirmatory phase III data become available.

References:

1. Lexitas Pharma Services and Ocusun enroll first patient in a pilot study for an upcoming phase III clinical trial evaluating investigational eye drop for age-related cataract. News release. Lexitas Pharma Services. July 14, 2026. Accessed July 15, 2026. https://www.prnewswire.com/news-releases/lexitas-pharma-services-and-ocusun-enroll-first-patient-in-a-pilot-study-for-an-upcoming-phase-iii-clinical-trial-evaluating-investigational-eye-drop-for-age-related-cataract-302824020.html

2. Daszynski DM, Santhoshkumar P, Phadte AS, et al. Failure of oxysterols such as lanosterol to restore lens clarity from cataracts. Sci Rep. 2019;9(1):8459. doi:10.1038/s41598-019-44676-4

3. A multicenter, randomized, double-masked, placebo-controlled pilot study to evaluate the efficacy and safety of ZOC2017217 in subjects with age-related cataract. ClinicalTrials.gov identifier: NCT07395986. Updated June 2026. Accessed July 15, 2026. https://clinicaltrials.gov/study/NCT07395986